RET and medullary thyroid gland carcinoma: Recent studies reported that mutations at solvent front (G810R/S/C/V), hinge (Y806C/N) and β2 strand (V738A) sites within the RET kinase domain can mediate acquired resistance to selpercatinib and pralsetinib in RET fusion-positive NSCLC and in RET-mutant medullary thyroid cancer [108,109] (Table 3).